Can a simple drug stop bleeding in stem cell patients?
NCT ID NCT07442513
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether etamsylate, a drug that helps blood clot, can prevent serious bleeding in people who have low platelets after a stem cell transplant. About 404 adults will receive either etamsylate or a placebo, and researchers will track who has a major bleed or dies within 30 days. The goal is to see if etamsylate reduces bleeding risk by at least 14% compared to placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can gut bacteria help rebuild immunity after stem cell transplants?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Cord blood cells aim to speed platelet recovery in transplant patients
- Platelet transfusions may influence blood vessel health in critically ill patients
- Could virtual reality help patients recover faster from cell therapy?